Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
9.64% $0.364
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.20 mill |
EPS: | -0.420 |
P/E: | -0.870 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 6.06 mill |
Avg Daily Volume: | 0.168 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.870 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.15x |
Company: PE -0.870 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.317 - 0.411 ( +/- 12.91%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-14 | Hull Andrew | Sell | 42 | Employee Stock Option (Expiration) |
2024-03-04 | Hsu Eric C | Sell | 309 | Employee Stock Option (Expiration) |
2024-01-21 | Mancini Alexandra Diane Janet | Sell | 121 | Employee Stock Option (Expiration) |
2024-02-20 | Jagpal Netta | Sell | 50 000 | Employee Stock Option (Right to Buy) |
2024-02-21 | Hull Andrew | Buy | 37 500 | Common Stock |
INSIDER POWER |
---|
73.91 |
Last 93 transactions |
Buy: 1 291 573 | Sell: 391 310 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.364 (9.64% ) |
Volume | 0.0598 mill |
Avg. Vol. | 0.168 mill |
% of Avg. Vol | 35.55 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.